logo
Our top 3 gainers and laggards over the past month as the S&P 500 hits record highs

Our top 3 gainers and laggards over the past month as the S&P 500 hits record highs

CNBC4 hours ago
The stock market has been on a tear over the past month, as Wall Street mulled over quarterly earnings reports, President Donald Trump 's tariff moves, and the Federal Reserve's next monetary policy decision. Since last month's third annual meeting of the CNBC Investing Club, the S & P 500 and Nasdaq hit nine and 14 record closing highs, respectively. Both stock benchmarks hit those milestones again Wednesday. From our July 11 gathering at the New York Stock Exchange to Wednesday's market close, the S & P 500 advanced more than 3.3% and the tech-heavy Nasdaq gained roughly 5.5%. The market lost some ground Thursday morning after the July producer price index came in hotter than expected. That PPI followed Tuesday's rather benign July consumer price index , which boosted stocks and raised expectations for a Federal Reserve interest rate cut during its September meeting. Despite the hot PPI, a rate cut next month still remains pretty much a lock, according to the CME FedWatch tool . The odds, however, did dim slightly on the prospect of two more rate reduction before the end of 2025. The big questions for investors and the Fed have been whether Trump's tariffs will rekindle worrisome inflation and hurt the labor market. After all, fostering price stability and maximum employment are the pillars of the central bank's dual mandate. Back on Aug. 1, the government's jobs report was released and showed some signs of cracks as July non-farm payroll growth was much weaker than expected, and the additions taken together from the prior two months were revised sharply lower. Over the past month, we picked our spots in over a dozen trades — both taking profits and adding to positions. The Club started a new position in Cisco Systems on July 17 and made two subsequent buys of the computer networking equipment powerhouse's shares. Cisco reported its fiscal 2025 fourth quarter after Wednesday's close, beating estimates on both the top and bottom lines with a slightly better-than-expected guidance kicker. We're going to talk more about Cisco and the Club's other 30 positions during Thursday's monthly meeting, which will be livestreamed at noon ET. The recorded video will be available to members later in the afternoon. The reaction to earnings reports was behind the portfolio's best and worst-performing names over the past month. GE Vernova , for example, can thank its blowout earnings release for sending the industrial stock to No. 1. Conversely, the biggest laggard was Eli Lilly, which had its worst session in years following disappointing results for a key late-stage trial. Here's a breakdown of our three best and three worst-performing stocks over the past month ahead of Thursday's August monthly meeting. Winners GE Vernova up 17.6% GEV YTD mountain GE Vernova (GEV) year-to-date performance Shares surged after the power equipment maker posted a strong quarter and raised guidance last month. GE Vernova makes products to support the energy grid, which needs more juice to support all the AI data centers being built. The stock hit a record high that session, and several more since the July 23 earnings release. Jim Cramer described the industrial name as "maybe the best story in the entire market" as a result. The Club raised its GE Vernova price target by $150 to $700 per share due to the company's growing backlog and strong demand. Still, we reiterated our 2 rating, which means we would want to wait for a pullback before adding to our position. On July 17, the Club booked some profits in a small sale of GE Vernova just in case ahead of the Street's lofty quarterly expectations. Broadcom up 12.7% AVGO YTD mountain Broadcom (AVGO) year-to-date performance Broadcom led the recent rally in chip stocks. Nvidia was our fourth-best performer since July's annual meeting. The group, in part, received a boost after Trump said he would exempt companies from his planned semiconductor tariffs if they committed to invest in U.S. manufacturing. News such as Samsung's $16.5 billion deal to supply semiconductors to Tesla improved investor sentiment around the AI trade as well recently. We did, however, sell some Broadcom last week after the stock's big run and ahead of its quarterly earnings report. The trim doesn't reflect a change in our conviction. Instead, we're anticipating some profit-taking after Broadcom's quarterly report on Sept. 6, and we wanted to get ahead of that. That's been a trend amongst its peers, at least. Advanced Micro Devices shares dropped 7% in a session following its earnings report last week despite management issuing upbeat guidance. Apple up 10.5% AAPL YTD mountain Apple (AAPL) year-to-date performance Rounding out our top three performers was Apple. Shares of the iPhone maker saw an initial boost following quarterly earnings report in late July. Investors cheered Apple's biggest revenue growth since 2021, and CEO Tim Cook's remarks about more generative AI investments. But the bulk of Apple's gains came last week. Apple announced an additional $100 billion investment into domestic manufacturing, bringing the company's total U.S. investment to $600 billion over the next four years. The news showcased Cook's ability to get on a better footing with the Trump administration to mitigate tariff headwinds. Laggards Eli Lilly down 16.7% LLY YTD mountain Eli Lilly (LLY) year-to-date performance The drugmaker has had a rough month. Eli Lilly stock initially moved lower in late July after rival Novo Nordisk, the company's main competitor in GLP-1s, lowered its 2025 sales growth outlook. The Club made a sale of Eli Lilly as a result, locking in big profits. The bulk of Lilly's losses, however, came in early August. Alongside its earnings release on Aug. 7, the company revealed subpar results from a late-stage trial on its weight loss pill. The stock, in turn, had its worst session in years. As a result, we lowered our Eli Lilly price target to $800 from $1,000 and downgraded the stock to our 3 rating. That view shifted Wednesday, with our double upgrade back to our buy-equivalent 1 rating after CEO David Ricks and several other company insiders bought lots of shares of the depressed stock. CrowdStrike down 9.7% CRWD YTD mountain CrowdStrike (CRWD) year-to-date performance Shares have experienced a consistent decline amid broader weakness in the cybersecurity sector. CrowdStrike stock, for example, shed 5% in a single session earlier this month following negative commentary from peer Fortinet's management team regarding the highly anticipated firewall refresh cycle. That didn't make sense to us because CrowdStrike is cloud-native and doesn't sell traditional firewall equipment. The negative sentiment spread to fellow Club holding Palo Alto Networks , too, as shares fell despite management never hyping up the refresh cycle. That's because sometimes when a stock in a certain sector plunges, it can bring down its peers, even if the others have nothing to do with the reason why it's down. Palo Alto stock has recently been digging itself out of the big hole left following the July 29 rumors of a CyberArk deal and the official announcement by the company a day later. Salesforce down 8.2% CRM YTD mountain Salesforce (CRM) year-to-date performance Shares have slumped with the rest of the enterprise software names. Part of the stock's weakness can be attributed to investor concerns about generative AI's impact on software-as-a-service (SaaS) companies like Salesforce. The emerging technology poses a risk to Salesforce's seat-based licensing models and, in turn, its sales growth. This week's "AI ate software" note from Melius Research outlined these worries, prompting us on Monday to downgrade Salesforce to a hold-equivalent 2 rating. Still, we're holding on to see if Salesforce's Agentforce, its set of AI tools, will help the stock in the long run. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

More Americans are driving to Canada than Canadians to the U.S., report finds
More Americans are driving to Canada than Canadians to the U.S., report finds

Yahoo

time23 minutes ago

  • Yahoo

More Americans are driving to Canada than Canadians to the U.S., report finds

More American travellers drove to Canada in July than Canadians did to the United States, according to a new report by Statistics Canada. This is the first time such a reversal has taken place since before the COVID-19 pandemic. The dramatic decline of Canadians travelling to the U.S. was sparked last year, with U.S. President Donald Trump's heated rhetoric about Canada becoming the 51st state that led to an ongoing trade war and lingering tension between the two countries. The data for last month shows that 1.8 million American residents drove to Canada, compared to the 1.7 million Canadian residents who made a return trip from the U.S. by car. Canadian road trips to U.S. plunge for seventh month as boycott continues Both countries saw a decline at land border crossings last month. For Americans driving to Canada, there was a slight dip of 7.4 per cent compared to the same month last year. It was also the sixth consecutive month of year-over-year declines. However, the decline was much steeper for Canadians returning from the U.S. this July compared to the previous year, at nearly 37 per cent. Last month marked the seventh consecutive month of year-over-year declines, StatCan said. 'In 2024, Canadian-resident trips to the United States totalled 39 million, representing 75 per cent of all Canadian-resident travel abroad,' according to another StatCan report published earlier this summer about travel to the U.S. 'However, recent data on foreign travel suggest that Canadians' travel sentiment toward their southern neighbour has been shifting in early 2025.' Although the data reflects a 'notable change in travel patterns,' StatCan said it is 'unclear whether the change is temporary or part of a more permanent shift.' As for air travel, the number of non-resident visitors who flew to Canada increased in July. There were 1.4 million of them — up by just over 3 per cent since the same time last year. While the bump was largely due to residents who came from overseas (up 5.6 per cent this year), American travellers were also up by just under 1 per cent. The highest number of U.S.-resident arrivals by air was 31,600 Americans on July 3, before the Independence Day long weekend in the U.S. Meanwhile, the number of Canadians returning home from abroad by air last month was down by 5.3 per cent compared to the previous year. In particular, Canadians flying back from the U.S. also decreased by nearly 26 per cent since the same time last year. Canadian permanent residents will now have to pay 'visa integrity fee' to enter U.S. Here's what it is An American sent to Canada was shocked by how furious Canadians are at the U.S. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

Yahoo

time23 minutes ago

  • Yahoo

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

Yahoo

time23 minutes ago

  • Yahoo

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store